Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7019MR)

This product GTTS-WQ7019MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7019MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4611MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ14592MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ4731MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ2070MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ628MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ3790MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ15103MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ13965MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW